Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Decreases By 62.7%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 15,500 shares, a drop of 62.7% from the January 31st total of 41,500 shares. Approximately 1.0% of the company’s shares are sold short. Based on an average trading volume of 143,200 shares, the short-interest ratio is presently 0.1 days.

Institutional Trading of Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC acquired a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals at the end of the most recent reporting period. 1.95% of the stock is owned by institutional investors and hedge funds.

Sonoma Pharmaceuticals Stock Up 3.2 %

Sonoma Pharmaceuticals stock traded up $0.07 during trading hours on Friday, reaching $2.27. 25,438 shares of the company’s stock were exchanged, compared to its average volume of 43,747. The firm’s 50 day simple moving average is $2.61 and its 200 day simple moving average is $2.61. Sonoma Pharmaceuticals has a twelve month low of $2.15 and a twelve month high of $9.37. The firm has a market capitalization of $3.67 million, a PE ratio of -0.56 and a beta of 1.43.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings results on Wednesday, February 5th. The company reported ($0.59) earnings per share for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 68.98% and a negative net margin of 26.82%. Analysts anticipate that Sonoma Pharmaceuticals will post -0.67 EPS for the current year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.